GlassScriptPhysician profile
Inamul Khan
NPI 1265726939
$2,276.18
in general payments reported to CMS, 2019-2025
9 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 80% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2023: $342 · 2024: $627 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636 · Travel and Lodging: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,636.38 |
| Travel and Lodging | $516.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $666.56 | 2025 | Clottriever Bold Catheter, Flowtriever, Ct Thrombectomy System Kit |
| Shionogi INC | $615.15 | 2023-2025 | Fetroja |
| Abbvie INC. | $298.94 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $200.53 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $148.55 | 2024 | Andexxa |
| Csl Behring | $122.38 | 2024 | Kcentra |
| La Jolla Pharmaceutical Company | $118.48 | 2023 | Giapreza |
| Chiesi USA, INC. | $81.30 | 2025 | Cleviprex |
| Inari Medical, INC. | $24.29 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inamul Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.